Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders

AIM: In a recent randomized, multicenter trial (NCT02814838) a short-term anti-inflammatory treatment with ladarixin (LDX; an inhibitor of the CXCR1/2 chemokine receptors) did not show benefit on preserving residual beta cell function in new-onset type 1 diabetes. We present a post hoc analysis of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sordi, Valeria, Monti, Paolo, Lampasona, Vito, Melzi, Raffaella, Pellegrini, Silvia, Keymeulen, Bart, Gillard, Pieter, Linn, Thomas, Bosi, Emanuele, Rose, Ludger, Pozzilli, Paolo, Giorgino, Francesco, Cossu, Efisio, Piemonti, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319139/
https://www.ncbi.nlm.nih.gov/pubmed/37409229
http://dx.doi.org/10.3389/fendo.2023.1175640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319139/
https://www.ncbi.nlm.nih.gov/pubmed/37409229
http://dx.doi.org/10.3389/fendo.2023.1175640

Ejemplares similares